CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics

Adcetris (brentuximab vedotin) - Takeda, Pfizer

https://library.ehaweb.org/eha/2022/eha2022-congress/357065/carmelo.carlo-stella.camidanlumab.tesirine.updated.efficacy.and.safety.in.an.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Aot_id%3D26856%2Amarker%3D1751%2Afeatured%3D17676

Carmelo Carlo-Stella; Stephen Ansell; Pier Luigi Zinzani; John Radford; Kami Maddocks; Antonio Pinto; Graham P. Collins; Veronika Bachanova; Nancy Bartlett; Isabelle Bence-Bruckler; Mehdi Hamadani; Justin Kline; Jiri Mayer; Kerry J. Savage; Ranjana Advani; Paolo Caimi; René-Olivier Casasnovas; Tatyana Feldman; Brian Hess; Mariana Bastos-Oreiro; Sunil Iyengar; Sandy Eisen; Yanina Negievich; Luqiang Wang; Jens Wuerthner; Alex F. Herrera

May 13, 2022